-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Pharmaceutical starts Phase I/II trial of SYS6062 for advanced solid tumors in China

PUBT·11/05/2026 10:25:04
Listen to the news
CSPC Pharmaceutical starts Phase I/II trial of SYS6062 for advanced solid tumors in China
  • CSPC Pharmaceutical Group announced Nov. 5, 2026, the launch of its Phase I/II SYS6062 trial for advanced solid tumors in China.
  • The first-in-human study follows Chinese regulatory clearance in October 2026. Participant recruitment and screening are underway.
  • SYS6062 is an antibody-drug conjugate targeting CEACAM5, designed to kill tumor cells and surrounding cancer cells.
  • The multicenter trial will assess safety, tolerability and preliminary antitumor activity, alongside how the drug behaves in the body.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12402543), on November 05, 2026, and is solely responsible for the information contained therein.